Brian Levy
CEO @ Ocunexus Therapeutics
Brian Levy is a seed investor at Ocunexus Therapeutics focused on E-Commerce and Beauty. Brian Levy, OD, MSc has served as our Chief Medical Officer since January 2012. From 1994 to 2008, Dr. Levy was at Bausch + Lomb, Inc. where he served in various roles including Vice President of Research & Development, Corporate Vice President of Research & Development and Chief Medical Officer. Prior to joining Bausch + Lomb, Inc., Dr.Levy was in private clinical practice in Toronto, Ontario from 1980 to 1989, and from 1989 to 1994 he served as an Associate Professor in the Department of Ophthalmology at California Pacific Medical Center in San Francisco. He has also served as Chief Operating Officer at Danube Pharmaceuticals from 2008 to 2010 and Chief Scientific Officer at Nexis Vision from 2010 to 2011, both small venture-backed companies developing products in Ophthalmology. Dr. Levy currently holds an appointment as Clinical Professor in the Department of Ophthalmology at the University of Rochester's School of Medicine. Dr. Levy received his Doctor of Optometry degree from the University of California at Berkeley and did his post-graduate work in comparative anatomy and physiology of the eye at the University of Waterloo in Canada, where he received a MS degree.
- Total investments:
- 4
- Last investment:
- Lead investor:
- 0%
Last updated:
For AI agents: llms.txt
Industries Brian Levy invests in
Stages Brian Levy invests in
Countries Brian Levy invests in
Round sizes
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Round size
- Seed
- $2.5M–$3.7M
Investment Focus
Industry
- E-Commerce 2 (50%)
- Beauty 1 (25%)
- Retail 1 (25%)
- Eyewear 1 (25%)
- Fashion 1 (25%)
Stage
- Seed 2 (50%)
- Series A 1 (25%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Willow
|
Willow is stylish affordable disposable underwear that offers comfort, confidence, and leak-free protection, delivered discreetly to your door at a fraction of the price. Current options on the market are either expensive or bulky and generally lacking in style — plus, you have to purchase them at the store. Willow’s product is the thinnest andmost absorbent on the market, and has better odor control than other products. It’s extremely "breathable” and wicks liquid away from skin, just like sportswear. Best of all, Willow’s stylish products cost less than others because they are sold directly to the consumer, with no mark up by stores. | $2.5M / Seed / Jul 31, 2018 | |
HUBBLE
|
Hubble is the first brand of contact lenses sold directly to consumers through an e-commerce, subscription-only model. | $16.5M / Series A / Mar 07, 2017 | |
|
HUBBLE
|
Hubble is the first brand of contact lenses sold directly to consumers through an e-commerce, subscription-only model. | $3.7M / Seed / Oct 15, 2016 | |
|
HUBBLE
|
Hubble is the first brand of contact lenses sold directly to consumers through an e-commerce, subscription-only model. | $3.5M / Seed / May 01, 2016 |
Co-Investors
About Ocunexus Therapeutics
Ocunexus Therapeutics is a biopharmaceutical company that develops therapeutics for unmet clinical needs in ophthalmology. The company specializes in developing highly differentiated drug candidates based upon a novel mechanism of action called “Gap Junction Channel Modulation.” It has developed treatments for multiple front- and back-of-the-eyediseases and disorders that would potentially alter the standard of care. In addition, the company's technologies are expected to be transferable to other acute and chronic disease indications.Ocunexus is formerly known as CoDa Therapeutics, a pharmaceutical company focused on the development and commercialization of wound care therapeutics based on gap junction modulation. The company is based in San Diego, California.
Ocunexus Therapeutics Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Alexis White
Clinical Research Manager
|
|||
|
Brian Levy
CEO
|
|||
Colin Green
Chief Scientist
|
|||
David E. Eisenbud
Chief Medical Officer
|
|||
David Pool
Chief Financial Officer
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Featured in Investor Lists
Recommended lists
FAQ
What does Brian Levy invest in?
Brian Levy invests primarily in E-Commerce, Beauty and Retail startups, most often at Seed and Series A stage. Most of the 4 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Brian Levy's check size?
Brian Levy typically joins rounds of $2.5M–$3.7M at Seed. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Brian Levy participates in.
How do I contact Brian Levy?
Public channels for Brian Levy include LinkedIn. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Brian Levy last invest?
The most recent investment recorded for Brian Levy closed in Jul 2018. Shizune tracks 4 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
